23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test Directly to Consumers

Feb 19, 2015

|

NEW YORK (GenomeWeb) – 23andMe has received clearance from the US Food and Drug Administration to market its first health-related test, for Bloom syndrome, directly to consumers.

The test determines whether a healthy person carriers a genetic variant that could be passed on to a child. Bloom syndrome is an autosomal recessive disorder that results in short stature and a predisposition to cancer. The child must inherit two abnormal alleles in order to have symptoms of the syndrome.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

New Privacy Coalition

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

Less Sweat, More Diverse Microbiome

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

Oh, This Code

The Wall Street Journal examines billing codes used by uBiome.

PNAS Studies Look at Lung Cancer LncRNA, Hi-C Clustering, and More

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.

Featured White Papers

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

24

Featured Webinar

Comparison of Group B Streptococcus Molecular Assays for Routine Screening in Pregnant Women

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul

25

Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Menu